Globe Newswire (Mon, 17-Aug 8:31 AM ET)
Globe Newswire (Thu, 30-Jul 8:31 AM ET)
Globe Newswire (Mon, 27-Jul 4:30 PM ET)
Globe Newswire (Thu, 23-Jul 8:31 AM ET)
Globe Newswire (Thu, 9-Jul 4:01 PM ET)
Globe Newswire (Mon, 22-Jun 4:45 PM ET)
Globe Newswire (Wed, 27-May 8:31 AM ET)
AIDX Plans Ebola and Hantavirus Lab Readiness as Public Health Risks Mount
Market Chameleon (Fri, 22-May 5:53 AM ET)
Market Chameleon (Wed, 25-Feb 4:07 AM ET)
20/20 Biolabs Inc is a commercial stage diagnostics company with the core mission of developing and commercializing clinical laboratory tests for early disease detection and prevention and associated software that is powered by machine learning and real-world data to improve diagnostic accuracy and clinical utility. The company offers two OneTest lab products; OneTest for Cancer that inludes primary MCED blood test and revenue source post-COVID and OneTest for Longevity that consists of inflammatory biomarkers.
20/20 Biolabs trades on the NASDAQ stock market under the symbol AIDX.
As of August 25, 2026, AIDX stock price climbed to $0.53 with 43,055 million shares trading.
AIDX has a beta of 3.10, meaning it tends to be more sensitive to market movements. AIDX has a correlation of 0.05 to the broad based SPY ETF.
AIDX has a market cap of $6.75 million. This is considered a Sub-Micro Cap stock.
Last quarter 20/20 Biolabs reported $730,571 in Revenue and -$.26 earnings per share. This beat revenue expectation by $94,571 and missed earnings estimates by -$.14.
The top ETF exchange traded funds that AIDX belongs to (by Net Assets): VXF.
AIDX support price is $.48 and resistance is $.56 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that AIDX shares will trade within this expected range on the day.
